Kornimate/medical-research-clean huggingface dataset:
overnight use of electroacustimulation on postoperative nausea and vomiting in the outpatient surgery population

Conditions: Post-operative Nausea and Vomiting

Summary: postoperative nausea and vomiting after outpatient surgery are significant sources of patient dissatisfaction. the prevention of postoperative nausea and vomiting (ponv) should be equally as important as prevention of pain because both are large sources of patient dissatisfaction and can necessitate admission after routine outpatient procedures. none of the currently available pharmacological interventions are able to totally abolish ponv. the use of electroacustimulation is a useful adjunct in prevention of ponv, but has yet to be studied when the patient takes the device home with them after leaving an outpatient facility.

the goal of this project is to perform a pilot study to determine if sending patients home with the electroacustimulation device will decrease their ponv and subsequently increase their overall satisfaction. the primary outcome will be post-operative nausea and vomiting scores on a scale of 1-10 based on surveys which will be performed at 30m, 60m, 120m, and 24h post-op. secondary outcomes will be the amount of rescue nausea medications required by the patients, time to discharge, subjective pain assessment and the impact of their symptoms on the activities of daily living since being discharged from the surgery center based on survey, and amount of narcotic received. this project would also aim to reduce the amount of time patients spend in recovery post-operatively, reduce hospital admissions secondary to persistent nausea and vomiting, and educate students and trainees about alternative methods of treating and preventing postoperative nausea and vomiting.

Eligibility criteria:
inclusion criteria: • scheduled for outpatient surgery procedure under general anesthesia exclusion criteria: * pregnancy * currently experiencing menstrual symptoms * cardiac pacemaker * previous experience with acupuncture therapy * pharmacologic treatment for nausea or vomiting in the 24 hours prior to surgery

Keywords: post-operative post-op nausea vomiting
efficacy of intravenous fosfomycin in the treatment of complicated urinary in real-life conditions.

Conditions: Complicated Urinary Tract Infection

Summary: this will be a prospective observational multicentre study in real-life conditions of patients with complicated urinary infection of community presentation caused by escherichia coli using intravenous fosfomycin, quinolones or beta-lactams. it's a multicenter and multinational study and it will include 200 patients in the fosfomycin cohort and 200 patients in the control cohort (quinolones or beta-lactams).

the objectives are: 1. to asses the clinical and microbiological efficacy and safety of intravenous fosfomycin in the treatment of complicated urinary tract infections due to escherichia coli in real life conditions, in comparison with a matched cohort of patients treated with quinolones or beta-lactams. 2. to evaluate the frequency of microbiological failure and development of resistance (or decrease in sensitivity) in escherichia coli isolates, depending on different pharmacokinetic and pharmacodynamic parameters, with special emphasis on fauc0-24/mic. 3. to evaluate the frequency of microbiological failure and development of resistance (or decrease in sensitivity) and their association with the existence of basal mutations in genes related to intracellular transport or regulation of these transporters. for objective 1, a study of prospective mated cohorts (fosfomycin cohort versus quinolones or beta-lactams cohort) will be performed, and for objectives 2 and 3 a prospective cohort study (fosfomycin cohort) will be conducted.

Eligibility criteria:
fosfomycin cohort: * inclusion criteria: patients over 18 years of age. patients who have started treatment with intravenous fosfomycin, estimated that they will require at least 2 days of treatment with fosfomycin, initiated as either as empirical treatment (within 24 hours after the emergency visit or onset of symptoms) or targeted treatment (within 24 hours of the availability of the antibiogram). * exclusion criteria: patients under 18 years of age. patients in palliative treatment. control cohort (objective 1): * inclusion criteria:patients over 18 years of age. patients who have started treatment with intravenous quinolones or beta-lactams, estimated that they will require at least 2 days of treatment with the drug, initiated as either as empirical treatment (within 24 hours after the emergency visit or onset of symptoms) or targeted treatment (within 24 hours of the availability of the antibiogram). each patient from the fosfomycin cohort will be matched with a patient from this control cohort according to their. * exclusion criteria: patients under 18 years of age.patients in palliative treatment; informed consent not signed by the patient.

Keywords: prospective follow-up study real-life conditions complicated urinary tract infection escherichia coli infection fosfomycin efficacy quinolones beta-lactams microbiological failure resistance development
metabolic biomarkers in hashimoto's thyroiditis and psoriasis

Conditions: Hashimoto Disease; Psoriasis

Summary: hashimoto's disease (ht) and psoriasis (pso) have a significant impact on patient's quality of everyday life, and early diagnosis is critical for the symptoms management and prognosis. there is evidence that ht and pso share common metabolic pathways that relate to their pathogenesis, and are affected by dietary and lifestyle factors. previous studies have identified potential metabolic biomarkers, although the small number of studies hamper their validation. of note, most studies are not longitudinal thus do not capture the metabolic fluctuations in response to disease progression or dietary changes. thus, the purpose of this study is to identify metabolic biomarkers of ht and pso and study the role of epigenetic factors (diet and lifestyle) on the involved metabolic pathways . in addition, a comparative analysis of the disease-related quality of life (qol) will be performed in relation to dietary changes to unravel possible links between the qol and the associated metabolic pathways in ht and pso.

patients with hashimoto's thyroiditis (ht), patients with psoriasis (pso), and healthy individuals aged 18-60 will be recruited and assessed according to inclusion/exclusion criteria. eligible participants will be randomized to two groups. the intervention group will receive a combinational nutraceuticals plan for 6 months as part of a mediterranean diet and the control group will follow usual diet. data will be collected at baseline and at the end of the study including levels of organic and fatty acids, lifestyle and anthropometric measurements, adherence to mediterranean diet through the mediterranean diet score (mds) and disease-specific quality of life through the thyroid patient report outcome (thypro) and the dermatology life quality index (dlqi) questionnaires for the ht and the pso group respectively.

Eligibility criteria:
hashimoto's thyroiditis: * clinical findings * presence of thyroid autoantibodies (anti-tpo) in laboratory tests * gray-scale ultrasound findings. psoriasis: * presence of psoriatic lesions * psoriasis area and severity index score (pasi). healthy group: non-obese (bmi\<30) * non-athletes * non-pregnant or lactating women * not been diagnosed with a chronic or acute disease * not receiving antidepressants, drugs and supplements * normal thyroid stimulating hormone (tsh) levels or high tsh and absence of other clinical findings of thyroid malfunction. exclusion criteria: * malignant or congenital goiter * thyroidectomy

Keywords: metabolomics biomarkers metabolic pathways
analysis of lipid profiles in samples sperm and seminal plasma under artificial insemination

Conditions: Primary Infertility

Summary: identify, by lipidomics approaches, biochemical markers of fertility / infertility in sperm and seminal plasma linking the success or failure of the artificial insemination (iui)

analyze lipid profiles in samples of sperm and seminal plasma of three populations: 1. male sperm donors 2. men assigned to a program of assisted reproduction with normal sperm / slightly abnormal successfully in the iui; 3. attached to a program of assisted reproduction with male semen normal / slightly abnormal unsuccessfully in iui establish partnerships between the composition of fatty acids, especially fatty acids polyunsaturated (pufa) of the omega-3 (w3) series of samples analyzed parameterssemen and results of the ia to identify biochemical markers of fertility. assess markers found by checking the increase in the rate of success in the ia.

Eligibility criteria:
inclusion criteria group a women donor group * fallopian unobstructed men donor group * appear as sperm donor * age between 18-35 years * sexual abstinence 3-5 days exclusion criteria group a: * uterine malformations (fibroids, adenomyosis, uterine malformations or acquired congenital) and fallopian tubes (tubal occlusion) * obesity bmi (body mass index)\> 30 kg / m2 * presence of altered tubal toxic habits (smoking\> 15 cigarettes per day, alcohol or drug abuse). inclusión / exclusion criteria group b and c: * ≤ 38 years * natural cycles and stimulated * the criteria inclusion / exclusion group a * time sterility not exceeding three years.
the xenera™ 1 study tests xentuzumab in combination with everolimus and exemestane in women with hormone receptor positive and her2-negative breast cancer that has spread

Conditions: Breast Neoplasms

Summary: the main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with hr+/ her2- advanced or metastatic breast cancer and non-visceral disease.


Eligibility criteria:
inclusion criteria: * documented histologically confirmed breast cancer with erand/ or pgr-positive and her2-negative status * locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy * archival tumour sample available at the time of informed consent and provided to the central laboratory around the time of randomisation. patients must provide a formalin-fixed paraffin embedded (ffpe) tissue biopsy sample preferably taken at the time of presentation with recurrent or metastatic disease (provision of a biopsy sample taken from the bone is not acceptable). * patients must satisfy the following criteria for prior therapy: * disease progression during treatment or within 12 months of completion of endocrine adjuvant therapy or * disease progression while on or within 1 month after the end of prior endocrine therapy for advanced/metastatic breast cancer (note: the endocrine therapy does not have to be the treatment immediately prior to trial entry). * patients must have * at least one measurable non-visceral lesion according to recist version 1.1 in either lymph nodes, soft tissue, skin and/or * at least one measurable non-visceral lesion according to recist version 1.1 as lytic or mixed (lytic + blastic) in bone and/or * at least one non-measurable (lytic, mixed lytic + blastic, or blastic) bone lesion according to recist version 1.1 * eastern cooperative oncology group (ecog) performance score 0 or 1. * fasting glucose \<8.9 mmol/l (\<160 mg/dl) and hba1c \<8.0% * adequate organ function exclusion criteria: * previous treatment with agents targeting the igf pathway, akt, or mtor pathways * prior treatment with exemestane (except adjuvant exemestane stopped \>12 months prior to start of study treatment as long as the patient did not recur during or within 12 months after the end of adjuvant exemestane) * evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases, malignant pleural effusions, malignant peritoneal effusions) at screening. note: patients with a past history of visceral metastases are eligible if visceral metastases have completely resolved at least 3 months * history or evidence of metastatic disease to the brain * leptomeningeal carcinomatosis * more than 1 prior line of chemotherapy for hr+ her2- metastatic breast cancer * radiotherapy within 4 weeks prior to the start of study treatment * use of concomitant systemic sex hormone therapy * history or presence of cardiovascular abnormalities * known pre-existing interstitial lung disease * further exclusion criteria apply
effect of nebulized budesonide and oral corticosteroids on wheezing episode relapse in children

Conditions: Asthma

Summary: subjects aged 1-8 years who have been discharged from the emergency department/outpatient care facility with a diagnosis of asthma/bronchospasm/wheezing after usual standard care will be enrolled into this open-label, randomized, parallel-group study to compare the efficacy of nebulized budesonide and oral corticosteroids in preventing asthma exacerbation relapse rates during the 21-day follow-up period.

secondary outcomes include urinary cortisol-creatinine rations, symptom severity scores and peak flow rates.

Eligibility criteria:
inclusion criteria: * children ages 1-8 years old * discharge from emergency department/outpatient clinic with a diagnosis of asthma exacerbation after usual standard care * subjects must be able to show efficient use with a jet nebulizer exclusion criteria: * subjects requiring hospitalization * subjects receiving oral steroids 1 week prior to presentation to emergency department. * subjects with fev1 \< 50% of predicted * subjects with co-morbid medical conditions (renal or cardiovascular disease) * subjects with reported history of hiv * subjects unable to follow up for study visits * subjects who are frequently enuretic

Keywords: asthma
effectiveness and safety of firmagon® in androgen ablative therapy of advanced hormone-dependent prostate carcinoma in argentina

Conditions: Advanced Hormone Dependent Prostate Cancer

Summary: prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with firmagon® according to routine medical practice in argentina


Eligibility criteria:
inclusion criteria: * advanced prostate cancer patients to be treated with firmagon in the context of usual clinical practice * written informed consent exclusion criteria: * contraindications to firmagon * patients already on firmagon therapy
prospective comparison of 18f-fdg and 18f-fet pet for response evaluation in patients with primary central nervous system lymphoma

Conditions: Patients With Suspected or Diagnosed Central Nervous System Lymphoma

Summary: the overall goal of this imaging trial is to prospectively compare the usefulness of 18f-fdg pet and 18f-fet pet in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.


Eligibility criteria:
inclusion criteria: in order to be eligible for participation in this trial, the subject must: * be ≥ 19 years of age. * patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected of central nervous system lymphoma by anatomical imaging examination such as mri. * patients who have results or are planning to examine 18f-fdg pet in the above patients. exclusion criteria: the subject must be excluded from participating in the trial if the subject fulfil any single criteria described below: * pediatric and adolescent patients under 19 years of age. * the patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) to children. * patients with diagnosed or suspected lymphoma lesions in organs other than the cetral nervous system. * based on the investigator's judgement, if the patient makes it impossible to collect complete data for a clinical trial due to personal or other reasons. * patients who cannot stably have pet/ct due to claustrophobia, dyskinesia, anxiety disorder, seizure, etc. * based on the investigator's judgement, if the patient has a serious and/or uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic renal disease or chronic liver disease, etc.)
behavioral intervention study for better breast and cervical cancer control for korean american women

Conditions: Breast Cancer; Cervical Cancer

Summary: the long-term goal of this study is to build a sustainable,community-based outreach program using korean american community health workers (chws) to promote breast and cervical screening among korean american women, thereby reducing related morbidity and mortality. the study is designed to determine the effectiveness of a health literacy-focused tailored breast and cervical cancer control intervention delivered by chws. the investigators hypothesized that, compared to ka women in the delayed intervention group, ka women who receive a health literacy-focused chw intervention will demonstrate: (1) higher levels of adherence to screening for breast and cervical cancer, (2) greater levels of health literacy, (3) higher levels of breast and cervical cancer knowledge, and (4) improve decisional balance.

despite considerable progress in u.s. cancer control over the past 20 years, certain ethnic minority groups continue to experience significant health disparities. recent immigrants including korean americans (ka), face an unequal cancer burden related to the significant language and cultural barriers they face in attempting to navigate the u.s. healthcare system. ka women have the second highest incidence of cervical cancer nationally and are experiencing rapid increases in breast cancer incidence. not only are their breast and cervical cancers diagnosed at significantly later stages than those of whites, but they are also the least likely racial/ethnic group to receive early breast and cervical cancer screening. this community-based behavioral intervention is designed 1) to evaluate, in a randomized controlled trial, the effects of our health literacy-focused cancer control intervention, delivered by trained chws, on the primary outcomes: mammography and papanicolaou(pap)test screening adherence, in a sample of 360 ka women, 2)to test the effects of the proposed intervention on the secondary outcomes: level of health literacy, breast and cervical knowledge, and decisional balance, in the ka sample.

Eligibility criteria:
inclusion criteria: 1. age 21-65 years 2. self-identified as a ka woman 3. no mammogram and pap test within the last 18 months 4. able to read and write korean or english 5. willing to provide written study consent 6. willingness to provide written consent to allow the researchers to audit medical records for mammography and pap test use. exclusion criteria: 1. potential participants with a cancer diagnosis, an acute and/or terminal condition 2. psychiatric diagnosis (e.g., schizophrenia or cognitive impairment), or other conditions 3. women who have undergone hysterectomy

Keywords: ethnic minority women cancer screening health literacy behavioral intervention breast cancer screening cervical cancer screening
use of new drug qrx-3 for prevention and treatment of chronic kidney disease progression

Conditions: Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure

Summary: chronic kidney disease ckd is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the united states alone. ckd is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . in this study we are using a novel drug to target improved function of the kidneys.

chronic kidney disease has been linked to impaired activity of mitochondrial dysfunction along with oxidative intracellular mechanisms that result in the cascade of progressive damage within renal tubular cells. several treatment options for mitochondrial dysfunction have been suggested to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the nad/nad+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers . qrx-3 is a formulated novel drug designed to supply and optimize nad+ mitochondrial availability and prevent this nephron loss . in this study we evaluate the effect of intervention with this novel drug therapy on chronic kidney disease ckd population with slowly declining renal function.

Eligibility criteria:
inclusion criteria: * inclusion criteria * patient with chronic kidney disease * estimated glomerular function by mdrd of less than 60mls/min * patients with declining renal function ( as measured by egfr by mdrd ) * rate of decline of egfr over the last one year of less than 20% * negative serology markers for ckd etiology * provider perceived adherence to study follow up exclusion criteria: rapid rate of decline in kidney function of \> 20 % over last one year * symptomatic renal failure * presence of any suspected acute renal failure superimposed * presence of cast , hematuria, or abnormal urinalysis outside of simple uti * no known reversible cause of renal decline
post-market safety and performance outcomes of the vivere® bovine pericardial bioprosthetic valve

Conditions: AORTIC VALVE DISEASES; Aortic Valve Stenosis and Insufficiency; Aortic Valve Surgery; Mitral Valve Regurgitation; Mitral Valve Surgery

Summary: this study aims to collect post-market safety and performance data related to the procedure and follow-up of the vivere bovine pericardial bioprosthetic valve, when used in accordance with the product's instructions for use (ifu).

a multicenter, observational, retrospective, single-arm study. this study will include patients who underwent valve replacement (native or bioprosthetic) of the aortic or mitral valves using the vivere bovine pericardial bioprosthetic valve, between 2017 and 2022. data will be collected up to 3 years post-procedure.

Eligibility criteria:
inclusion criteria: * all patients who received the vivere® bovine pericardial bioprosthetic valve for replacement of the native valve or bioprosthesis in the aortic or mitral position, in accordance with the instructions for use (ifu). * patients aged \> 18 years. exclusion criteria: * patients who received the vivere® bovine pericardial bioprosthetic valve for replacement of the tricuspid or pulmonary valve. * contraindications specified in the ifus.